PET Imaging Targeting Granzyme B Predicts Immunotherapy Efficacy in Diffuse Large B-cell Lymphoma
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 150
- 试验地点
- 1
- 主要终点
- The value of PET imaging targeting granzyme B in predicting the efficacy of immunotherapy for diffuse large B-cell lymphoma
研究概览
简要总结
This study aims to investigate the predictive value of PET imaging targeting granzyme B on the outcome of patients with diffuse large B lymphoma receiving immunotherapy.
详细描述
The investigators will number all participants, create a medical record file, and record their basic information (gender, age) as well as contact information and medical history information. All participants will undergo 68Ga-grazytracer PET at baseline and after one course of immunotherapy (CAR-T, Glofitamab or iR2 ).
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Pathologic diagnosis of DLBCL
- •Patient's general condition is good and survival is expected to be greater than six months
- •Signed and dated informed consent form
排除标准
- •Combined with other malignant tumors
- •Patients with serious medical conditions who, in the opinion of the investigator, are not suitable for participation in this clinical study
- •Pregnant women and women at risk of pregnancy, breastfeeding women
- •poor compliant
结局指标
主要结局
The value of PET imaging targeting granzyme B in predicting the efficacy of immunotherapy for diffuse large B-cell lymphoma
时间窗: Baseline and 2 weeks after treatment
The value of PET imaging targeting granzyme B in predicting the efficacy of immunotherapy for diffuse large B-cell lymphoma
Standardized uptake value (SUV)
时间窗: Baseline and 2 weeks after treatment
SUV of 68Ga-grazytracer uptake on PET/CT images for tumor lesions
次要结局
- Overall survival(3 years)
- Progress free suivival(3 years)